2. Academic Validation
  3. Molecular docking, synthesis and biological evaluation of Vascular Endothelial Growth Factor (VEGF) B based peptide as antiangiogenic agent targeting the second domain of the Vascular Endothelial Growth Factor Receptor 1 (VEGFR1D2) for anticancer application

Molecular docking, synthesis and biological evaluation of Vascular Endothelial Growth Factor (VEGF) B based peptide as antiangiogenic agent targeting the second domain of the Vascular Endothelial Growth Factor Receptor 1 (VEGFR1D2) for anticancer application

  • Signal Transduct Target Ther. 2020 Jun 5;5(1):76. doi: 10.1038/s41392-020-0177-z.
Afsaneh Sadremomtaz 1,  Ameena M Ali 1 2,  Foroozan Jouyandeh 3,  Saeed Balalaie 4,  Razieh Navari 4,  Sylvain Broussy 5,  Kamran Mansouri 6,  Matthew R Groves 7,  S Mohsen Asghari 8 9
Affiliations

Affiliations

  • 1 XB20 Drug Design, Groningen Research Institute of Pharmacy, University of Groningen, 9700 AD, Groningen, The Netherlands.
  • 2 Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Doha, Qatar.
  • 3 Department of Biology, Faculty of Sciences, University of Guilan, Rasht, Iran.
  • 4 Peptide Chemistry Research Center, K.N. Toosi University of Technology, K. N. Toosi University of Technology, Tehran, Iran.
  • 5 University of Paris, Faculty of Pharmacy of Paris, CiTCoM, 8038 CNRS, U 1268 INSERM, F-75006, Paris, France.
  • 6 Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran.
  • 7 XB20 Drug Design, Groningen Research Institute of Pharmacy, University of Groningen, 9700 AD, Groningen, The Netherlands. m.r.groves@rug.nl.
  • 8 Department of Biology, Faculty of Sciences, University of Guilan, Rasht, Iran. sm_asghari@guilan.ac.ir.
  • 9 Institute of Biochemistry and Biophysics (IBB), University of Tehran, Tehran, Iran. sm_asghari@guilan.ac.ir.
PMID: 32499505 DOI: 10.1038/s41392-020-0177-z
Figures
Products